Drugs / CD70 CAR-NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06696846 | Dec 2024 → Nov 2027 expected | T-cell non-Hodgkin lymphoma, acute myeloid leukemia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD70 CAR-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06696846 ↗ |
| Modality | Cell therapy | “CAR - NK cells constructed by using genetic engineering technology retain the original extensive tumor - killing ability of NK cells.” NCT06696846 ↗ |
| Target | CD70 | “CD70-targeted CAR-NK cells” NCT06696846 ↗ |